

Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care

Received 10/11/2023
Review began 10/15/2023
Review ended 10/19/2023
Published 10/28/2023

© Copyright 2023

Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Tanishq Kumar¹, Rajoshee R. Dutta¹, Swedaj Thakre¹, Arihant Singh², Vivek R. Velagala¹, Raju K. Shinde²

1. Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND
2. General Surgery, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND

Corresponding author: Tanishq Kumar, tanishq2209@gmail.com

Abstract

Breast cancer is one of the most common types of cancer affecting women worldwide. Over the years, breast cancer has become a major public health concern, and its incidence is rising globally. The treatment of breast cancer does not stop with surgical intervention, but adjuvant therapies are administered to improve patient outcomes post-surgery based on the type of breast cancer diagnosed. This review focuses on the value of hormone therapy (HT) in improving the prognosis of breast cancer patients and why adhering to adjuvant treatment post-surgery is difficult for patients. HT aims to reduce the chances of breast cancer recurrence after surgical treatment. Even though HT is life-saving, patients tend to not adhere to the therapy due to various factors such as side effects, age-related issues, and socioeconomic status. Most patients stop adhering to the therapy as the duration can be as long as 5-10 years, and the quality of life is greatly impacted due to the side effects of the treatment. This review examines the possible factors leading to non-adherence to HT and tries to propose possible interventions that might improve patient compliance with the treatment. This article not only focuses on the impact of side effects of HT on patients' quality of life but also tries to understand the problems faced by breast cancer patients in adhering to HT.

Categories: Internal Medicine, General Surgery, Oncology

Keywords: aromatase inhibitors, tamoxifen, adherence, breast cancer, hormone therapy


Introduction And Background

Breast cancer is one of the most prevalent forms of cancer affecting women all over the world. Its incidence varies globally and is found to be lower (below 50 per 100,000) in the majority of developing countries compared to developed countries where the incidence is well above 50 per 100,000 people [1]. Even though the incidence is high in developed nations, advancements in screening, early detection, and treatment have reduced mortality rates in these patients. Based on a report in 2019, the death rate due to breast cancer in North America was 12.6 per 100,000 while 13.36 per 100,000 in Europe [2]. In contrast, the mortality rate in Central and Eastern Europe and Africa was approximately 15.5 per 100,000 and 18.4 per 100,000 respectively [1].

The mortality rates have been low compared to the incidence rates due to continuous breakthroughs in treating and managing breast cancer. One such advancement has been the development of long-term hormone therapy (HT) for patients who are hormone receptor (HR)-positive cases, constituting a major proportion of breast cancer-diagnosed cases [3]. The most common drugs used in endocrine therapy (ET) are tamoxifen or an aromatase inhibitor (AI). Adjuvant treatment with HT post-surgery has proved to reduce the recurrence and mortality rates in breast cancer patients [4,5]. This article examines the factors affecting adherence to HT, its side effects, and the interventions that can be made to improve adherence to HT in breast cancer patients. Figure 1 provides a summary of factors affecting adherence to treatment, side effects, and interventions to improve adherence.

How to cite this article

Kumar T, Dutta R R, Thakre S, et al. (October 28, 2023) Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care. Cureus 15(10): e47869. DOI 10.7759/cureus.47869



Review

Methodology

Eligibility Criteria

The eligibility criteria included articles that discussed factors affecting adherence to HT. Articles focusing on the side effects of HT, and interventions that can improve adherence to HT in breast cancer management were also included. Articles that focused only on the treatment of breast cancer were excluded. There were no other exclusion criteria.

Literature Search Strategy

All authors were involved in the literature search. The PubMed electronic database was used for the literature search. We searched for relevant articles published from the year 1999 to the year 2022. The following key terms were used in the search: "Hormone Therapy," "Breast Cancer," "Adherence," "Tamoxifen," and "Aromatase inhibitors."

Data Extraction

The abstracts of the articles generated by the literature search were reviewed by all authors independently. Those that met the selection criteria were studied and assessed for their full texts. The search process is illustrated in the flow chart in Figure 2.




FIGURE 2: PRISMA flow diagram depicting the screening and selection of articles

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Hormone therapy

HT is used for treating hormone-receptor-positive breast cancer cases, which account for nearly 85% of all types of breast cancer [6]. HT aims to stop any interaction between estrogen and estrogen-based biochemical reactions that might trigger cancer cells [7]. HT is based on blocking signaling between estrogen and tumor cells. Disruption of estrogen receptors occurs either by directly binding to the receptor, which can be observed in estrogen receptor agonists/antagonists (ERAs) drugs like tamoxifen, or by diminishing estrogen synthesis by AIs like letrozole, anastrozole, and exemestane. One of the most common drugs under use for both pre and postmenopausal patients is tamoxifen [7]. Nearly all female patients with HR-positive breast cancer are advised to undergo HT. If the regimen is strictly followed, HT can potentially lower breast cancer recurrence by 40% and the death rate by almost a third [8]. When HR-positive breast cancer is diagnosed, usually HT is initiated except in cases when adjuvant chemotherapy is also to be given. In such scenarios, HT starts after chemotherapy is over. Based on recurrence risk and the type of HT regimen, the ideal treatment duration could be around 5-10 years. Even though the benefits of HT are many, non-adherence to the therapy is reported to be very high. Nearly 50% of the women administered with HT do not take 100% of their recommended dose [9,10]. Almost 50% of the patients stop adhering to the regimen in the fifth year of starting their therapy [11,12].

Adherence and non-adherence

Adherence, in medical terms, is defined as the degree of compliance exhibited by a patient in following an agreed disease management prescribed by a healthcare professional [13]. Not complying with the approved treatment plan by making lapses either by missing or taking extra doses of the prescribed medications is termed as non-adherence. Non-adherence can be classified based on behavior into types: unintentional and intentional non-adherence. Unintentional non-adherence could be due to a confusing medication plan, poor understanding of the doses, or physical or mental disability. On the other hand, the intentional decision to avoid the prescribed medical management comes under intentional non-adherence [14]. According to a World Health Organisation report, if a patient's adherence level ranges from 80% to 120% with regard to the recommended regimen for a considerable duration, then that patient can be put under the adherent category [13].

Side effects of hormone therapy

Side effects of HT are one of the main reasons for non-adherence to it. These side effects not only reduce the quality of life on a daily basis but also have some psychological as well as physical implications. Some of the most common side effects are joint pain/osteoporosis, depressive episodes, hot flashes, difficulty sleeping,

fatigue, anxiousness, and weight-related issues [15-21]. Poor knowledge about these side effects and lack of constant support to the patients lead to non-adherence to HT, defeating the rationale behind initiating HT [12].

Hobson's choice or on the horns of a dilemma

A study revealed that most HR-positive breast cancer patients give consent to HT because they think they have no other treatment options. The risk of recurrence and the mandatory nature of the treatment regimen for HR-positive breast cancer leaves the patients with no choice. This scenario is called Hobson's choice. It means when there is no other feasible option with similar outcomes. Sometimes, this proves to be beneficial for some patients as a large number of patients follow the entire regimen till its completion, whereas knowledge about the side effects after initiating the HT or having their own experience with the side effects gives rise to a horned dilemma. It refers to having two similar negative options, making the decision to opt for any of them difficult. One possibility is to start the HT and endure the side effects till the prescribed duration. Another option is to not start the therapy and take their chances with regard to the recurrence of tumor cells [1].

A study based on interviews revealed that a segment of patients adhere to the prescribed therapy believing they are left with no option (Hobson's choice). At the same time, patients who are skeptical about HT experience a dilemma (horned dilemma) after enduring the side effects of the therapy. Eventually, due to the side effects, what started as Hobson's choice now puts the patient in a dilemma of reconsidering their decision to adhere to HT. The change in the outlook towards the therapy arises due to the side effects now overshadowing the benefits of the therapy, leading them to non-adherence to HT [22].

Factors influencing adherence to hormone therapy

Psychological Factors

Several studies have shown that the issue of non-adherence to the prescribed regimen is not simple. It does not solely originate from disease management, economic status, anthropometric measurements, or the different healthcare modalities. Now, it is understood that non-adherence is complex and difficult to quantify [23]. Psychological characteristics of the individual patient also contribute to the compliance or non-compliance towards the regimen. Some of the psychological perceptions related to HT include prescribed treatment plans, quality of life, effect on mental health, risk of recurrence, and patient-doctor relationship. Patients tend to fall into the dilemma of whether HT should be continued to avoid recurrence or discontinued, thereby risking relapse of cancer. These factors tend to influence adherence and non-adherence of patients toward HT in breast cancer [24].

Based on the findings of several studies, patients' personal viewpoints regarding the regimen prescribed by healthcare professionals are conflicted. The weighing of benefits against the side effects constantly causes confusion in adhering to the regimen [17]. A study showed that patients did not believe in the drugs' efficacy, leading to non-adherence [25]. Another study found that around 17% of patients did not follow the regimen after two years since they were not optimistic about the treatment, and side effects outweighed the benefits. In this group, patients gave more value to the quality of life. They were ready to face the risk of recurrence and probably shortened life span, too, rather than experiencing severe side effects of HT. [26]. On the other hand, patients who were more knowledgeable about the benefits followed the treatment plan involving tamoxifen and endured the side effects. This group was found to be more adherent to the hormone therapy. Managing the side effects by prescribing more drugs might play a role in contributing to non-adherence. A study found that emotions like optimism, self-belief, faith in HT, and trust in the healthcare personnel proved to be of key importance and contributed significantly to such adherent patients reporting fewer side effects of psychological illness than non-adherent patients [17].

Age of the Patients

The age of the patients also plays a role in adherence and non-adherence to the HT. Studies have revealed that patients who were very young or very old were non-adherent to HT [27]. This could be due to different age-related complications or expectations. In young patients, fear of losing fertility and daily hardships due to side effects of HT could contribute to non-adherence [28]. Poor quality of life in young patients would contribute to psychological illness and loss of faith in the treatment, leading to non-adherence to HT. [29]. On the other hand, old age comes with its own problems, such as chronic diseases, lack of proper knowledge regarding HT, poor social support, and lower motivation [30,31]. These studies suggest that patients at extreme ends of the age spectrum are at higher risk of being non-adherent to HT. Hence, healthcare workers should focus more on such patients and try to solve their misconceptions, doubts, or any modifiable concerns that might lead to positive outcomes for the patient.

Severity of the Disease

Patients suffering from terminal stages tend to adhere more to HT [32]. Sometimes, high-dose hormone therapy influences the patients' thinking and makes them realize their condition might be serious;

therefore, such patients adhere more to HT. This might explain the higher degree of compliance seen in patients undergoing chemotherapy compared to patients who do not go through chemotherapy [33]. Sometimes, a high dose of HT might influence the patients towards non-adherence due to the side effects affecting the quality of life. Therefore, it is subjective to comment regarding patients' perception of the nature of HT and the stage of the disease [34].

Social and Economic Status

One of the most important aspects of any treatment is the patient's socioeconomic status, as the burden of chronic disease management might pose the greatest hurdle for the patient's management. Socioeconomic factors like financial situation, literacy, and social well-being of the patient actively influence the compliance and outcome of the treatment. Based on a study, it was found that lower or no payment for HT increased the compliance of the patients [35]. Another study found that even after receiving free medications for treatment, patients still did not follow the prescribed regimen. This suggests that socioeconomic status is not the sole reason patients do not fully comply with HT [36].

Interventions to improve adherence

Communication Between Doctors and Patients

Doctor-patient relationship in chronic disease management plays an important role in the outcome of the disease. A good professional relationship between the healthcare provider and the patient ensures great disease management. Based on a study, it was found that patients tend to remain adherent to HT if the doctor-patient relationship is good. A good relationship can be achieved when a doctor provides easy access to medical support, periodic assessment of the effectiveness of HT, and constant psychological support [37]. A study found that sometimes doctors unintentionally fail to elaborate on the chronic HT treatment plan and do not emphasize the side effects of the treatment and how it will influence the quality of life. Therefore, it is the duty of the doctor to make sure that patients have a complete understanding of their disease and HT [38]. It has been proved that patients with poor knowledge regarding HT, the potential side effects, and the impact on the quality of life tend to become non-adherent to HT [39,40]. On the other hand, patients who were well-oriented about the treatment plan and its side effects showed higher degrees of adherence to HT [41]. Therefore, good doctor-patient communication is often associated with effective adherence to HT [42].

Managing Side Effects

HT comes with its benefits and side effects. For some patients, side effects outweigh the benefits of the HT, and they become non-adherent to the treatment. Therefore, healthcare personnel should focus on managing the side effects, which will increase the rate of patients complying with HT in breast cancer management [12].

Social Support

A recent study focusing on understanding the impact of social support in breast cancer patients found that social support improves the degree of adherence to HT. Social support in the form of information circulated by healthcare providers increased their knowledge regarding the treatment plan, side effects, benefits, and positive outcomes of HT on complete adherence. Empathy, positivity, and sympathy from members of the family, friends, and cancer support groups help to motivate the patient to complete HT [43].

Future Studies and Scope of Research

Future studies can focus on the behavioral psychology of patients in adhering to HT. Various reasons for adherence or non-adherence based on behavioral patterns can be understood. Studies based on improving the quality of life can lead to long-term HT adherence [27].

Conclusions

Breast cancer is a highly prevalent global health issue affecting people in all countries with varying incidence rates. Even though incidence rates are higher in developed nations compared to developing economies, these countries have lower mortality rates due to advanced screening tools, early detection, and disease management. One breakthrough in improving the outcomes for breast cancer survivors has been the introduction of HT, which significantly reduces recurrence and death rates if the patients adhere to the treatment regimen. However, several patients tend to become non-adherent to HT. This non-adherence is a culmination of several factors, such as side effects of the therapy, patient beliefs about the regimen, psychological implications of the treatment, disease severity, and socioeconomic status of the patients. Patients end up having a Hobson's choice due to no alternative treatment options, forcing them to start HT despite its side effects. After initiating the treatment, the patients face a horned dilemma due to the side effects influencing their daily lives. This confuses patients as they compare the positive against the

negative aspects of the treatment and ponder whether they should continue the treatment or not.

Interventions such as effective doctor-patient communication, which help patients understand their treatment plan better as well as HT's benefits and side effects, will certainly increase adherence to HT. Healthcare providers should try to manage the side effects as much as possible to improve patient regimen compliance. Social support constituting family, friends, and cancer survivor groups increases patient's adherence to HT and enhances their chance of avoiding cancer recurrence. In this battle against the rising prevalence of breast cancer, issues related to HT should be addressed so that patients can reap the full benefits of this treatment. Research studies focusing on minimizing the side effects of HT or newer modalities of managing these side effects should be undertaken. Creating a protective bubble around the patients where doctors help them understand the disease better, social support giving them confidence, and continuous research in tackling breast cancer will surely increase our chances of winning the battle against breast cancer globally.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Tanishq Kumar, Rajoshee R. Dutta

Acquisition, analysis, or interpretation of data: Tanishq Kumar, Swedaj Thakre, Arihant Singh, Vivek R. Velagala, Raju K. Shinde

Drafting of the manuscript: Tanishq Kumar

Critical review of the manuscript for important intellectual content: Tanishq Kumar, Rajoshee R. Dutta, Swedaj Thakre, Arihant Singh, Vivek R. Velagala, Raju K. Shinde

Supervision: Tanishq Kumar, Raju K. Shinde

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. AlOmeir O, Patel N, Donyai P: Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. *Support Care Cancer*. 2020, 28:5075-84. [10.1007/s00520-020-05585-9](https://doi.org/10.1007/s00520-020-05585-9)
2. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol*. 2019, 30:781-7. [10.1093/annonc/mdz051](https://doi.org/10.1093/annonc/mdz051)
3. Spring LM, Gupta A, Reynolds KL, et al.: Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. *JAMA Oncol*. 2016, 2:1477-86. [10.1001/jamaoncol.2016.1897](https://doi.org/10.1001/jamaoncol.2016.1897)
4. Fabian CJ, Kimler BF: Selective estrogen-receptor modulators for primary prevention of breast cancer. *J Clin Oncol*. 2005, 23:1644-55. [10.1200/JCO.2005.11.005](https://doi.org/10.1200/JCO.2005.11.005)
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015, 386:1341-52. [10.1016/S0140-6736\(15\)61074-1](https://doi.org/10.1016/S0140-6736(15)61074-1)
6. Mesa-Eguiagaray I, Wild SH, Rosenberg PS, et al.: Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. *Br J Cancer*. 2020, 123:852-9. [10.1038/s41416-020-0938-z](https://doi.org/10.1038/s41416-020-0938-z)
7. Drăgănescu M, Carmocan C: Hormone therapy in breast cancer. *Chirurgia (Bucur)*. 2017, 112:413-7. [10.21614/chirurgia.112.4.413](https://doi.org/10.21614/chirurgia.112.4.413)
8. Davies C, Godwin J, Gray R, et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*. 2011, 378:771-84. [10.1016/S0140-6736\(11\)60993-8](https://doi.org/10.1016/S0140-6736(11)60993-8)
9. Moon Z, Moss-Morris R, Hunter MS, Norton S, Hughes LD: Nonadherence to tamoxifen in breast cancer survivors: a 12 month longitudinal analysis. *Health Psychol*. 2019, 38:888-99. [10.1037/hea0000785](https://doi.org/10.1037/hea0000785)
10. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat*. 2012, 134:459-78. [10.1007/s10549-012-2114-5](https://doi.org/10.1007/s10549-012-2114-5)

11. Hadji P, Ziller V, Kyvernitis J, Bauer M, Haas G, Schmidt N, Kostev K: Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. *Breast Cancer Res Treat.* 2013, 138:185-91. [10.1007/s10549-013-2417-1](https://doi.org/10.1007/s10549-013-2417-1)
12. Fleming L, Agnew S, Peddie N, Crawford M, Dixon D, MacPherson I: The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. *Breast.* 2022, 64:63-84. [10.1016/j.breast.2022.04.010](https://doi.org/10.1016/j.breast.2022.04.010)
13. Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J: Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. *Cochrane Database Syst Rev.* 2020, 5:CD012419. [10.1002/14651858.CD012419.pub2](https://doi.org/10.1002/14651858.CD012419.pub2)
14. Wroe AL: Intentional and unintentional nonadherence: a study of decision making. *J Behav Med.* 2002, 25:555-72. [10.1023/a:1015866415552](https://doi.org/10.1023/a:1015866415552)
15. Iacorossi L, Gambalunga F, Fabi A, Giannarelli D, Facchinetti G, Piredda M, De Marinis MG: Adherence to hormone therapy in women with breast cancer: a quantitative study. *Prof Inferm.* 2016, 69:113-21. [10.7429/pi.2016.692113](https://doi.org/10.7429/pi.2016.692113)
16. Shinn EH, Broderick G, Fellman B, Johnson A, Wieland E, Moulder S, Symmans WF: Simulating time-dependent patterns of nonadherence by patients with breast cancer to adjuvant oral endocrine therapy. *JCO Clin Cancer Inform.* 2019, 3:1-9. [10.1200/CCI.18.00091](https://doi.org/10.1200/CCI.18.00091)
17. Pan Y, Heisig SR, von Blanckenburg P, Albert US, Hadji P, Rief W, Nestoriuc Y: Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. *Breast Cancer Res Treat.* 2018, 168:667-77. [10.1007/s10549-017-4637-2](https://doi.org/10.1007/s10549-017-4637-2)
18. Kidwell KM, Harte SE, Hayes DF, et al.: Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. *Cancer.* 2014, 120:2403-11. [10.1002/cncr.28756](https://doi.org/10.1002/cncr.28756)
19. Kadakia KC, Snyder CF, Kidwell KM, et al.: Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. *Oncologist.* 2016, 21:539-46. [10.1634/theoncologist.2015-0549](https://doi.org/10.1634/theoncologist.2015-0549)
20. Jackisch C, Kreienberg R, Blettner M, et al.: Assessment of quality of life in postmenopausal women with early breast cancer participating in the PACT trial: the impact of additional patient information material packages and patient compliance. *Breast Care (Basel).* 2020, 15:236-45. [10.1159/000500771](https://doi.org/10.1159/000500771)
21. Bender CM, Gentry AL, Brufsky AM, et al.: Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. *Oncol Nurs Forum.* 2014, 41:274-85. [10.1188/14.ONF.274-285](https://doi.org/10.1188/14.ONF.274-285)
22. AlOmeir O, Patel N, Donyai P: Hobson's choice or a horned dilemma: a grounded theory on adherence to adjuvant endocrine therapy verified with breast cancer survivors. *Support Care Cancer.* 2022, 30:10127-36. [10.1007/s00520-022-07435-2](https://doi.org/10.1007/s00520-022-07435-2)
23. Montagna E, Zagami P, Masiero M, Mazzocco K, Pravettoni G, Munzone E: Assessing predictors of tamoxifen nonadherence in patients with early breast cancer. *Patient Prefer Adherence.* 2021, 15:2051-61. [10.2147/PPA.S285768](https://doi.org/10.2147/PPA.S285768)
24. Yusuf M, Nathan M, Wiley A, Russell J, Partridge A, Joffe H: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. *Breast Cancer Res Treat.* 2021, 185:53-62. [10.1007/s10549-020-05920-y](https://doi.org/10.1007/s10549-020-05920-y)
25. Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L: Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. *Support Care Cancer.* 2015, 23:3115-30. [10.1007/s00520-015-2685-x](https://doi.org/10.1007/s00520-015-2685-x)
26. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. *J Clin Oncol.* 2004, 22:3309-15. [10.1200/JCO.2004.11.064](https://doi.org/10.1200/JCO.2004.11.064)
27. Yussof I, Mohd Tahir NA, Hatah E, Mohamed Shah N: Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. *Breast.* 2022, 62:22-35. [10.1016/j.breast.2022.01.012](https://doi.org/10.1016/j.breast.2022.01.012)
28. Llarena NC, Estevez SL, Tucker SL, Jeruss JS: Impact of fertility concerns on tamoxifen initiation and persistence. *J Natl Cancer Inst.* 2015, 107:1-5. [10.1093/jnci/djv202](https://doi.org/10.1093/jnci/djv202)
29. Wenzel LB, Fairclough DL, Brady MJ, et al.: Age-related differences in the quality of life of breast carcinoma patients after treatment. *Cancer.* 1999, 86:1768-74.
30. Gellad WF, Grenard JL, Marcum ZA: A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. *Am J Geriatr Pharmacother.* 2011, 9:11-23. [10.1016/j.amjopharm.2011.02.004](https://doi.org/10.1016/j.amjopharm.2011.02.004)
31. Jacob L, Hadji P, Kostev K: Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany. *J Geriatr Oncol.* 2016, 7:169-75. [10.1016/j.jgo.2016.03.001](https://doi.org/10.1016/j.jgo.2016.03.001)
32. Wulaningsih W, Garmo H, Ahlgren J, et al.: Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. *Breast Cancer Res Treat.* 2018, 172:167-77. [10.1007/s10549-018-4890-z](https://doi.org/10.1007/s10549-018-4890-z)
33. Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Malacova E, Roughead EE: Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?. *Springerplus.* 2014, 3:282. [10.1186/2193-1801-3-282](https://doi.org/10.1186/2193-1801-3-282)
34. Bosco-Lévy P, Jové J, Robinson P, Moore N, Fourrier-Réglat A, Bezin J: Persistence to 5-year hormonal breast cancer therapy: a French national population-based study. *Br J Cancer.* 2016, 115:912-9. [10.1038/bjc.2016.276](https://doi.org/10.1038/bjc.2016.276)
35. Ma S, Shepard DS, Ritter GA, Martell RE, Thomas CP: Cost sharing for breast cancer hormone therapy: how do dual eligible patients' copayment impact adherence. *PLoS One.* 2021, 16:e0250967. [10.1371/journal.pone.0250967](https://doi.org/10.1371/journal.pone.0250967)
36. Persaud N, Bedard M, Boozary A, et al.: Adherence at 2 years with distribution of essential medicines at no charge: the CLEAN Meds randomized clinical trial. *PLoS Med.* 2021, 18:e1003590. [10.1371/journal.pmed.1003590](https://doi.org/10.1371/journal.pmed.1003590)
37. Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol.* 2003, 21:602-6. [10.1200/JCO.2003.07.071](https://doi.org/10.1200/JCO.2003.07.071)

38. Davidson B, Vogel V, Wickerham L: Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. *J Support Oncol*. 2007, 5:139-43.
39. Neugut AI, Hillyer GC, Kushi LH, et al.: Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the Breast Cancer Quality of Care Study (BQUAL). *Breast Cancer Res Treat*. 2012, 134:419-28. [10.1007/s10549-012-2066-9](https://doi.org/10.1007/s10549-012-2066-9)
40. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM: Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. *Med Care*. 2007, 45:431-9. [10.1097/01.mlr.0000257193.10760.7f](https://doi.org/10.1097/01.mlr.0000257193.10760.7f)
41. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC: Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. *Breast Cancer Res Treat*. 2013, 137:829-36. [10.1007/s10549-012-2387-8](https://doi.org/10.1007/s10549-012-2387-8)
42. Hurtado-de-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB: Behavioral interventions to enhance adherence to hormonal therapy in breast cancer survivors: a systematic literature review. *Clin Breast Cancer*. 2016, 16:247-55. [10.1016/j.clbc.2016.03.006](https://doi.org/10.1016/j.clbc.2016.03.006)
43. Toledo G, Ochoa CY, Farias AJ: Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors. *Support Care Cancer*. 2020, 28:271-8. [10.1007/s00520-019-04814-0](https://doi.org/10.1007/s00520-019-04814-0)